Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral Neuropathy

Inclusion Criteria: * Male or female, who is at least 18 years of age or older * Patients with clinical diagnosis of breast cancer * Patients planned to be treated with paclitaxel or docetaxel * Patients who can understand and sign the Informed Consent Form * Patients who can apply the study gel by himself /herself or has a giver that can apply the product. * Female patients of childbearing potential who agree to use a highly effective method of contraception throughout the study Exclusion Criteria: * Patient already treated with taxanes or other chemotherapies known to induce neuropathies * Patient with previously diagnosed peripheral neuropathy * Patient with concomitant therapies known to induce neuropathies * Patient treated for neuropathic pain * Patient with comorbid factors known to induce neuropathies (such as Diabetes, Alcoholism, HIV, Peripheral vascular disease, Vitamin B deficiencies) * Patient currently receiving monoamine oxidase (MAO) inhibitors therapy or patients on antidepressants which affect noradrenergic transmission e.g. tricyclic antidepressants and mianserin (as mentioned in the current topical brimonidine labeling of approved products). * Patient who will not be able to follow the protocol for physical or psychological reasons * Patient with history of skin disorders, significant skin disease, irritated skin or open wounds within the same body areas planned for the IMP application. * Known or suspected allergies or sensitivities to any components of any of the study drugs (see Investigator's Brochure/Product label) * Female who is pregnant or lactating * Female who intends to conceive a child during the clinical trial